ICI Therapy May Reduce Asthma Exacerbations
Patients receiving Immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months.
Tag: nivomulab Opdivo
ICI Therapy May Reduce Asthma Exacerbations
Patients receiving Immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months.
Read More
First Mesothelioma Therapeutic Approved in 16 Years
The FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
Read More
FDA OK’s Nivolumab And Ipilimumab Drug Combo for Non-small Cell Lung Cancer
The US Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with certain lung cancers.
Read MoreFDA Approves First Lung Cancer Immunotherapy
The US FDA has approved Nivolumab (Opdivo), the first immunotherapy to be available for use in the treatment of lung cancer.
Read More